World's Best Scientists 2026 revealed!
Award Badge
Immunology
USA
2026

D-Index & Metrics

Best Scientists

D-Index
166
Citations
115487
World Ranking
1001
National Ranking
593

Immunology

D-Index
167
Citations
120432
World Ranking
60
National Ranking
42

Medicine

D-Index
167
Citations
120444
World Ranking
583
National Ranking
339

Research.com Recognitions

  • 2026 - Research.com Immunology in United States Leader Award
  • 2025 - Research.com Immunology in United States Leader Award

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Immune system
  • Cancer

Nicholas P. Restifo spends much of his time researching Immunology, Cytotoxic T cell, Antigen, Immunotherapy and T cell. His work deals with themes such as Cancer and Cancer research, Melanoma, which intersect with Immunology. His studies deal with areas such as Molecular biology, CD8 and Cytokine as well as Cytotoxic T cell.

His Antigen research includes elements of Antibody and Virology. His work on Cancer immunotherapy and Cancer vaccine as part of general Immunotherapy study is frequently linked to Natural selection, therefore connecting diverse disciplines of science. Nicholas P. Restifo combines subjects such as Interleukin 2 and Dendritic cell with his study of T cell.

His most cited work include:

  • Cancer immunotherapy: moving beyond current vaccines. (2543 citations)
  • Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes (2452 citations)
  • Cancer regression in patients after transfer of genetically engineered lymphocytes (2174 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Immunology, Immunotherapy, T cell, Cytotoxic T cell and Antigen. Nicholas P. Restifo interconnects Cancer research and Melanoma in the investigation of issues within Immunology. His Cancer research study combines topics in areas such as Interleukin 12 and Cytokine.

His Immunotherapy research is multidisciplinary, relying on both Interleukin 2 and Oncology. In his study, Cellular differentiation is strongly linked to Cell biology, which falls under the umbrella field of T cell. His biological study spans a wide range of topics, including Molecular biology and Virology.

He most often published in these fields:

  • Immunology (56.89%)
  • Immunotherapy (32.00%)
  • T cell (30.89%)

What were the highlights of his more recent work (between 2014-2021)?

  • T cell (30.89%)
  • Cancer research (28.67%)
  • Immunotherapy (32.00%)

In recent papers he was focusing on the following fields of study:

Nicholas P. Restifo mainly focuses on T cell, Cancer research, Immunotherapy, Immunology and Adoptive cell transfer. The study incorporates disciplines such as Cell biology, Effector, CD8 and Cytokine in addition to T cell. His CD8 research is multidisciplinary, incorporating perspectives in Cytotoxic T cell and Tyrosine kinase.

The concepts of his Immunotherapy study are interwoven with issues in Melanoma, Oncology and Antigen. The Immunology study combines topics in areas such as Reprogramming and Disease. He has researched Adoptive cell transfer in several fields, including Antibody, Tumor-infiltrating lymphocytes, Cell therapy and Interleukin 15.

Between 2014 and 2021, his most popular works were:

  • Adoptive cell transfer as personalized immunotherapy for human cancer. (1238 citations)
  • A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response (412 citations)
  • Identification of essential genes for cancer immunotherapy (370 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Immune system
  • Cancer

His scientific interests lie mostly in Immunotherapy, Immunology, T cell, Cancer research and Adoptive cell transfer. Immunology is closely attributed to Cancer in his work. Nicholas P. Restifo has included themes like Epigenetics, CD8 and Cell biology in his T cell study.

He combines subjects such as Tumor microenvironment, Cytotoxic T cell and Chromatin with his study of CD8. His Cancer research research is multidisciplinary, incorporating elements of Effector, Cancer immunotherapy and T-cell receptor. His biological study spans a wide range of topics, including Oncology, Antigen, Internal medicine, Melanoma and Gene.

Best Publications

  • Cancer regression in patients after transfer of genetically engineered lymphocytes

    Richard A. Morgan;Mark E. Dudley;John R. Wunderlich;Marybeth S. Hughes

  • Cancer immunotherapy: moving beyond current vaccines.

    Steven A Rosenberg;James C Yang;Nicholas P Restifo

  • Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

    Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang

  • Adoptive cell transfer as personalized immunotherapy for human cancer.

    Steven A. Rosenberg;Nicholas P. Restifo

  • Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy

    Steven A. Rosenberg;James C. Yang;Richard M. Sherry;Udai S. Kammula

  • Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

    Steven A. Rosenberg;James C. Yang;Douglas J. Schwartzentruber;Patrick Hwu

  • A human memory T cell subset with stem cell-like properties

    Luca Gattinoni;Enrico Lugli;Yun Ji;Zoltan Pos

  • Adoptive cell transfer: a clinical path to effective cancer immunotherapy

    Steven A. Rosenberg;Nicholas P. Restifo;James C. Yang;Richard A. Morgan

  • Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

    Mark E. Dudley;John R. Wunderlich;James C. Yang;Richard M. Sherry

  • Adoptive immunotherapy for cancer: harnessing the T cell response

    Nicholas P. Restifo;Mark E. Dudley;Steven A. Rosenberg

  • Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

    Paul F. Robbins;Richard A. Morgan;Steven A. Feldman;James C. Yang

  • Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

    Giao Q. Phan;James C. Yang;Richard M. Sherry;Patrick Hwu

  • Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

    Laura A. Johnson;Richard A. Morgan;Mark E. Dudley;Lydie Cassard

  • Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

    Mark E. Dudley;James C. Yang;Richard Sherry;Marybeth S. Hughes

  • Adoptive immunotherapy for cancer: building on success.

    Luca Gattinoni;Daniel J. Powell;Steven A. Rosenberg;Nicholas P. Restifo

  • Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

    Richard A. Morgan;Nachimuthu Chinnasamy;Daniel Abate-Daga;Alena Gros

  • Defining ‘T cell exhaustion’

    Christian U Blank;W Nicholas Haining;Werner Held;Patrick G Hogan;Patrick G Hogan

  • Natural selection of tumor variants in the generation of “tumor escape” phenotypes

    Hung T. Khong;Nicholas P. Restifo

  • Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

    Luca Gattinoni;Steven E. Finkelstein;Christopher A. Klebanoff;Christopher A. Klebanoff;Paul A. Antony

  • Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

    Christopher A. Klebanoff;Luca Gattinoni;Parizad Torabi-Parizi;Keith Kerstann

  • T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

    Maria R. Parkhurst;James C. Yang;Russell C. Langan;Mark E. Dudley

  • Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

    Luca Gattinoni;Christopher A. Klebanoff;Christopher A. Klebanoff;Douglas C. Palmer;Claudia Wrzesinski

Frequent Co-Authors

Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Zhiya Yu
Zhiya Yu National Institutes of Health
Luca Gattinoni
Luca Gattinoni University of Regensburg
Douglas C. Palmer
Douglas C. Palmer National Institutes of Health
Christopher A. Klebanoff
Christopher A. Klebanoff Memorial Sloan Kettering Cancer Center
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Richard A. Morgan
Richard A. Morgan University of California, Los Angeles
Willem W. Overwijk
Willem W. Overwijk The University of Texas MD Anderson Cancer Center
Mark E. Dudley
Mark E. Dudley Novartis (Switzerland)
Francesco M. Marincola
Francesco M. Marincola National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related online degrees can open up diverse career opportunities in healthcare and research. Many students find accelerated pathways beneficial, such as enrolling in an accelerated fnp program to become a Family Nurse Practitioner, allowing faster entry into advanced clinical roles.

If you do not have a nursing background, starting with online RN programs designed for non nurses can be a great option. These online rn programs for non nurses provide essential training to build a strong foundation in patient care, which complements immunology knowledge.

For those looking for accessible routes into nursing, identifying the easiest accelerated nursing programs can help streamline the education process. These programs typically have flexible admission criteria and compressed timelines.

Additionally, starting a career through accredited lpn programs easy to get into offers a practical entry point into nursing roles, which can later be expanded with further specialization in immunology-related fields.

Best Scientists Citing Nicholas P. Restifo

Trending Scientists

Recently Published Articles